2024年6月5日～8日にかけて、イタリアのミラノでEASL Congress 2024が開催されました。
この会議は、臨床医、研究者、医療従事者、患者代表、業界専門家など、7,000人以上の専門家が一堂に会する肝臓学の分野でのヨーロッパ最大のイベントです。世界クラスの教授陣との双方向の議論を交わすことのできる数々の学習セッションがあり、肝臓学の権威と直接交流することのできる絶好の機会でした。
当教室からは、小川祐二医師と野上麻子医師が発表し、大変有意義な経験となりました。
その他、中島淳主任教授、米田正人医師の参加する共同研究も多数報告され、実りある会となりました。とりわけ、MASLDの治療薬のTirzepatide phase2の結果は、最終日に報告され、インパクトのある発表でした。
■筆頭発表
(POSTER PRESENTATIONS)
〈MASLD – Diagnostics and non-invasive assessment〉
The distribution of fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction associated steatotic liver disease in the general population.
Yuji Ogawa(Presenter), Wataru Tomeno, Masaru Baba, Imamura Yasushi, Michihiro Iwaki, Takashi Kobayashi, Asako Nogami, Kento Imajo, Asahiro Morishita, Takashi Honda, Miwa Kawanaka,Shigeru Mikami, Noriaki Manabe, Tomoari Kamada, Takumi Kawaguchi, Masato Yoneda, Satoru Saito, Atsushi Nakajima / 5 June 2024.
< Cirrhosis and its complications – Other clinical complications except ACLF and critical illness>
Pre-and post-test diagnostic concordance rates of TJLB for suspected liver and blood diseases.
Asako Nogami(Presenter), Naohiro Wada, Tomohiro Otani, Michihiro Iwaki, Takashi Kobayashi, Satoru Saito, Masato Yoneda, Atsushi Nakajima / 7 June 2024.
■共同研究者の発表
(Oral Presentations)
<GENERAL SESSION Ⅰ>
Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography – a multicenter cohort study of 10,920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) .
Terry Cheuk-Fung Yip,Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta,Elisabetta Bugianesi, Masato Yoneda, Minghua g, Hannes Hagström, Jerome Boursier, José Luis Calleja Panero, Boon Bee George Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun Sanyal, Victor De Lédinghen, Philip N Newsome, Jiangao Fan, Laurent Castera, Michelle Lai, Stephen Harrison, Céline Fournier-Poizat, Grace Lai-Hung Wong, Grazia Pennisi, Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc De Saint-Loup, Elba Llop Herrera, Kevin Kim Jun Teh, Carmen Lara Romero, Amon Asgharpour, Sara Mahgoub, Chan Mandy, Clémence M Canivet, Manuel Romero Gomez, Seung Up Kim, Vincent Wai-Sun Wong
6 June 2024.
<Late-breaker Orals>
Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial.
Rohit Loomba, Mark Hartman, Eric Lawitz, Raj Vuppalanchi, Jerome Boursier, Elisabetta Bugianesi, Masato Yoneda, Cynthia Behling, Oscar Cummings, Yuanyuan Tang, Bram Brouwers, Deborah Robins, Amir Nikooie, Mathijs Bunck, Axel Haupt, Arun J. Sanyal
７ June 2024.
< MASLD: Clinical aspects>
Validation of the Baveno VII ‘rule of 5’ in a real-life multicentre cohort of patients with metabolic dysfunction associated steatotic liver disease.
Elba Llop, Huapeng Lin, Hye Won Lee, Terry Cheuk-Fung Yip,Emmanuel Tsochatzis, Salvatore Petta,Elisabetta Bugianesi, Masato Yoneda, PhD, Ming-Hua Zheng,Hannes Hagström,Jérôme Boursier,George Boon-Bee Goh,Wah-Kheong Chan, Rocio Gallego-Durán,Arun J. Sanyal,Victor de Lédinghen,Philip N Newsome, Jian-Gao Fan,Laurent Castéra,Michelle Lai,Stephen Harrison,Céline Fournier-Poizat,Grace Lai-Hung Wong,Grazia Pennisi,Angelo Armandi,Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Kevin Kim Jun Teh,Carmen Lara-Romero,Amon Asgharpour,Sara Mahgoub,Mandy Chan, Clemence M Canivet,Manuel Romero-Gomez,Seung Up Kim,Vincent Wai-Sun Wong,José Luis Calleja
７ June 2024.
< MASLD – Diagnostics and non-invasive assessment>
The performance of the enhanced liver fibrosis test by cardiometabolic risk factors in patients with metabolic dysfunction-associated steatotic liver disease.
Kazuhito Kawata, Hirokazu Takahashi, Taeang Arai, Yuya Seko, Takeshi Chida, Hiedenao Noritake, Hidenori Toyoda, Hideki Hayashi,Kanji Yamaguchi, Michihiro Iwaki, Masato Yoneda,Toshihide Shima, Hideki Fujii, Asahiro Morishita, Kengo Tomita, Miwa Kawanaka, Yuichi Yoshida, Tadashi Ikegami, Kazuo Notsumata, Satoshi Oeda, Masanori Atsukawa, Yoshihiro Kamada, Yoshio Sumida, Hideaki Fukushima, Eiji Miyoshi, Shinichi Aishima, Takeshi Okanoue, Yoshito Itoh, Atsushi Nakajima
5 June 2024.
〈Cirrhosis and its complications – Portal Hypertension〉
Accuracy of spleen stiffness measurement for the diagnosis of high-risk esophageal varices in patients with advanced chronic liver disease: a systematic review and individual patient data meta-analysis.
Elton Dajti，Federico Ravaioli, Xialong Qi, Jinjun Chen, Horia Stefanescu，Young Seo Cho, Christophe Cassinotto, Rui Gaspar, Lory S. Crocè, Maha M. Elsabaawy, Mirella Fraquelli, Ivica Grgurevic, Carmen Fierbinţeanu-Braticevici, Grace LH Wong15, Renata Fofiu, Maciej K. Janik, Flavia Fernandes, Laure Elkrief, Pierre-Emmanuel Rautou, Atsushi Nakajima, Romanas Zykus, Matthias Buechter, Zhen Giovanni Galati, Thomas Reiberger, Ekaterina O. Liusina, Julia Arribas Anta, José Ignacio Fortea, Pik Eu Jason Chang, MD, Natalie Lucchina, Masashi Hirooka, Giorgio Soardo, Luigi Colecchia, Davide Roccarina, Fabio Piscaglia, Francesco Azzaroli，Giovanni Marasco, Annalisa Berzigotti, Agostino Colli, Davide Festi, Antonio Colecchia
8 June 2024.
< Alcohol-related liver disease and MetALD – Clinical>
Clinical characteristics, surveillance, treatment allocation and outcomes of alcohol-related hepatocellular carcinoma: meta-analysis of 37 studies and 66, 559 patients.
Daniel Tung, Rebecca Wenling Zeng, Christen En Ya Ong, Elden Ong, Charlotte Chung Hui Ong, Benedix Sim, Jia Hong Koh, Wen Hui Lim, Jieling Xiao, Nicholas Syn, Alfred Kow, Cheng Han Ng, Darren Jun Hao Tan, Sung Won Lee, Hirokazu Takahashi, Takumi KawaguchI, Nobuharu Tamaki, Atsushi Nakajima, Yock-Young Dan, Karn Wijarnpreecha, Mazen Noureddin, George Ioannou, Mark Muthiah, Margaret Teng, Rohit Loomba, Daniel Huang
8 June 2024.